Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

被引：3
|
作者：
Ilyas, Rimal [1 ]
Johnson, Isla McKerrow [1 ]
McCullough, Kristen [2 ]
Al-Kali, Aref [3 ]
Alkhateeb, Hassan B. [3 ]
Begna, Kebede [3 ]
Mangaonkar, Abhishek A. [3 ]
Litzow, Mark R. [3 ]
Hogan, William J. [3 ]
Shah, Mithun, V [3 ]
Patnaik, Mrinal M. M. [3 ]
Pardanani, Animesh [3 ]
Tefferi, Ayalew [3 ]
Gangat, Naseema [3 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Pharmacol, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165491
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1286 / 1287
页数：2
相关论文
共 50 条
  • [41] Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
    Coombs, Catherine C.
    Sallman, David A.
    Devlin, Sean M.
    Dixit, Shweta
    Mohanty, Abhinita
    Knapp, Kristina
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    Padron, Eric
    Arcila, Maria E.
    Klimek, Virginia M.
    van den Brink, Marcel R. M.
    Tallman, Martin S.
    Levine, Ross L.
    Rampal, Raajit K.
    Rapaport, Franck
    HAEMATOLOGICA, 2016, 101 (11) : E457 - E460
  • [42] Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)
    Salhotra, Amandeep
    Aribi, Ahmed
    Ngo, Dat
    Zhang, Jianying
    Sandhu, Karamjeet
    Al-Malki, Monzr
    Ali, Haris
    Koller, Paul
    Arslan, Shukaib
    Budde, Elizabeth
    Khaled, Samer
    Dadwal, Sanjeet
    Snyder, David S.
    Artz, Andrew
    Forman, Stephen
    Nakamura, Ryotaro
    Stein, Anthony
    Marcucci, Guido
    Aldoss, Ibrahim
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : E196 - E200
  • [43] Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients
    Zong, Lihong
    Yin, Minyue
    Kong, Jinyu
    Zhang, Jian
    Song, Baoquan
    Zhu, Jinzhou
    Xue, Shengli
    Wu, Xiaojin
    Wu, Depei
    Bao, Xiebing
    Qiu, Huiying
    MOLECULAR CARCINOGENESIS, 2023, 62 (10) : 1572 - 1584
  • [44] A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
    Shahswar, Rabia
    Gabdoulline, Razif
    Krueger, Katja
    Wichmann, Martin
    Goetze, Katharina S.
    Braitsch, Krischan
    Meggendorfer, Manja
    Schmalbrock, Laura
    Bullinger, Lars
    Modemann, Franziska
    Fiedler, Walter
    Krauter, Juergen
    Kaun, Stephan
    Rotermund, Susanne
    Voss, Andreas
    Behrens, Yvonne Lisa
    Bergmann, Anke Katharina
    Koller, Elisabeth
    Beutel, Gernot
    Thol, Felicitas
    Heidel, Florian
    Heuser, Michael
    LEUKEMIA, 2025, 39 (03) : 614 - 622
  • [45] Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
    Bataller, Alex
    Bazinet, Alexandre
    Dinardo, Courtney D.
    Maiti, Abhishek
    Borthakur, Gautam
    Daver, Naval G.
    Short, Nicholas J.
    Jabbour, Elias J.
    Issa, Ghayas C.
    Pemmaraju, Naveen
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Takahashi, Koichi
    Loghavi, Sanam
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD ADVANCES, 2024, 8 (04) : 927 - 935
  • [46] Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
    Gangat, Naseema
    Karrar, Omer
    Iftikhar, Moazah
    Mccullough, Kristen
    Johnson, Isla M.
    Abdelmagid, Maymona
    Abdallah, Mostafa
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek
    Saliba, Antoine N.
    Torghabeh, Mehrdad Hefazi
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Arana
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (02) : 193 - 202
  • [47] Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy
    Maurillo, L.
    Spagnoli, A.
    Candoni, A.
    Papayannidis, C.
    Borlenghi, E.
    Lazzarotto, D.
    Fianchi, L.
    Sciume, M.
    Zannier, M. E.
    Buccisano, F.
    Del Principe, M. I.
    Mancini, V.
    Breccia, M.
    Fanin, R.
    Todisco, E.
    Lunghi, M.
    Palmieri, R.
    Fracchiolla, N.
    Musto, P.
    Rossi, G.
    Venditti, A.
    LEUKEMIA RESEARCH, 2023, 127
  • [48] Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
    Morsia, Erika
    McCullough, Kristen
    Joshi, Maansi
    Cook, Joselle
    Alkhateeb, Hassan B.
    Al-Kali, Aref
    Begna, Kebede
    Elliott, Michelle
    Hogan, William
    Litzow, Mark
    Shah, Mithun
    Pardanani, Animesh
    Patnaik, Mrinal
    Tefferi, Ayalew
    Gangat, Naseema
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1511 - 1521
  • [49] Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2021, 138
  • [50] Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun Vinod
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD ADVANCES, 2022, 6 (17) : 5227 - 5231
12345